Bristol-Myers Squibb Aktie News

Bristol-Myers Squibb offers a compelling value at current lows, trading at under 7x earnings and yielding an attractive 6% dividend. BMY's resilient business model, strong cash flow, and growth from new drugs like Breyanzi offset legacy drug declines. Political risks are manageable for BMY as a US-based company, with potential policy changes likely to have limited impact on its bottom line.

UnitedHealth Group (NYSE:UNH ), Bristol-Myers Squibb (NYSE:BMY)  and Fiserv (NYSE:FI)  have been getting plenty of attention from big name investors.

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Alzheimers--BMS's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease.

Bristol Myers Squibb , Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and development.

Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed "TrumpRX.

The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-priced GASV Dogs—ET, MPLX, YRD, VZ, BMY, BBVA, and MFC—are highlighted as buyable for September 2025. Top ten GASV stocks are projected by analysts to deliver average net gains of 26.84% by September...

But Trump might get less than he bargained for as drugmakers focus on prices abroad, rather than stateside efforts.